Boundary Term in Metric f(R) Gravity: Field Equations in the Metric Formalism

The main goal of this paper is to get in a straightforward form the field equations in metric f(R) gravity, using elementary variational principles and adding a boundary term in the action, instead of the usual treatment in an equivalent scalar-tensor approach. We start with a brief review of the Einstein-Hilbert action, together with the Gibbons-York-Hawking boundary term, which is mentioned in some literature, but is generally missing. Next we present in detail the field equations in metric f(R) gravity, including the discussion about boundaries, and we compare with the Gibbons-York-Hawking term in General Relativity. We notice that this boundary term is necessary in order to have a well defined extremal action principle under metric variation.Comment: 12 pages, title changes by referee recommendation. Accepted for publication in General Relativity and Gravitation. Matches with the accepted versio

The delivery of personalised, precision medicines via synthetic proteins

Introduction: The design of advanced drug delivery systems based on synthetic and su-pramolecular chemistry has been very successful. Liposomal doxorubicin (Caelyx®), and liposomal daunorubicin (DaunoXome®), estradiol topical emulsion (EstrasorbTM) as well as soluble or erodible polymer systems such as pegaspargase (Oncaspar®) or goserelin acetate (Zoladex®) represent considerable achievements. The Problem: As deliverables have evolved from low molecular weight drugs to biologics (currently representing approximately 30% of the market), so too have the demands made of advanced drug delivery technology. In parallel, the field of membrane trafficking (and endocytosis) has also matured. The trafficking of specific receptors i.e. material to be recycled or destroyed, as well as the trafficking of protein toxins has been well characterized. This, in conjunction with an ability to engineer synthetic, recombinant proteins provides several possibilities. The Solution: The first is using recombinant proteins as drugs i.e. denileukin diftitox (Ontak®) or agalsidase beta (Fabrazyme®). The second is the opportunity to use protein toxin architecture to reach targets that are not normally accessible. This may be achieved by grafting regulatory domains from multiple species to form synthetic proteins, engineered to do multiple jobs. Examples include access to the nucleocytosolic compartment. Herein the use of synthetic proteins for drug delivery has been reviewed

Three linked risks for development in the Pacific Islands: climate change, disasters and conflict

Pacific Island countries are demonstrably vulnerable to the risks of climate change, disasters and conflict. This article outlines the conceptual links between these risks, briefly describes how each of the risks operates in the Pacific Islands, and goes on to demonstrate the interaction of climate change, disasters and potential for conflict in the Pacific Islands, by applying a new conceptual framework to some illustrative case studies. The case studies include relocation after the Gizo earthquake, ‘environmental refugees’ from sea level rise, and aggravation of the social issues of urbanization and unemployed youth by climate change. Fortunately, none of these cases has yet crossed the threshold into violent conflict, even though relocation of an affected community onto someone else's land is a particularly sensitive issue in the Pacific Islands